FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:2355-2357 May 28, 2009 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Delhommeau, F. PubMed Citation

The myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia (AML) are seemingly unrelated diseases except for their origin in hematopoietic precursor cells in bone marrow. A principal feature of the myeloproliferative disorders, which include polycythemia vera, essential thrombocythemia, and primary myelofibrosis, is overproduction of blood cells. By contrast, a prominent feature of the myelodysplastic syndromes is a reduction in the number of one or more cells in the hematopoietic lineage. In AML, primitive myeloid cells in the bone marrow do not differentiate into mature granulocytes. These three groups of bone marrow disorders are distinct, yet they have overlapping features. Moreover, . . . [Full Text of this Article]

Source Information

From the Human Oncology and Pathogenesis Program and the Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York (R.L.L.); and the Division of Hematology and Oncology, University of Pennsylvania, Philadelphia (M.C.).

This article has been cited by other articles:

• (2009). Novel Mutations in Myeloid Malignancies. JWatch Oncology and Hematology 2009: 1-1 [Full Text]